|
2/10/2010
MNIT is pleased to announce the publication of its 1st Newsletter of 2010. This Newsletter celebrates the sights and emotions of the 25th Gala Anniversary which was held in October 2009. Additionally, MNIT recognizes its OPO Partner in San Diego, LifeSharing and a Research Partner, nPOD.
|
|
6/17/2009
Come join MNIT, Saturday, October 3rd, 2009 at the Beverly Hills Hotel, in celebrating the lives, the accomplishments, and the history of MNIT and Dr. Rafael and Robert Mendez. The Doctors' Mendez founded the MNIT 25 years ago to improve the lives of transplant recipients. Through investments in science, research, and education, the MNIT has made a substantial difference in thousands of transplant recipient lives. To participate, please email us at GALA@transplantation.com
|
|
5/5/2009
OneLegacy, the Southern California OPO (Organ Procurement Organization) has mentioned MNIT in its latest Spring 2009 issue of 'The Bridge'; OneLegacy's Quarterly Newsletter.
From the Newsletter, "Unlike other medical laboratories, MNIT's labs focus exclusively on donor serology, offering the latest technology in screening and practices that are critical for donation to safely occure within very narrow time contraints".
For the complete text of this article, press the 'Read Article' button below.
|
|
4/21/2009
|
|
2/3/2009
|
|
2/2/2009
|
|
7/31/2008
Previous reports and NIT Laboratory data support the existence of persistent HCV RNA viremia in the absence of detectable anti-HCV1. Experience from blood donor screening suggests that the nucleic acid testing (NAT) can reduce so-called “window period” donations from organ donors during the antibody negative phase of acute HCV or HIV-1 infections2. In Sep 04’ the NIT laboratory decided to augment existing donor screening algorithm and introduced NAT testing using the Procleix HIV-1/HCV Assay (Chiron Corporation, Emeryville, CA). Accurate donor HCV and HIV-1 status is important in prevention of viral infection transmissions; HCV+ donors may be considered for HCV+ recipients. Infection must be identified in timely manner because of limited life of the donor organ
|
|
7/31/2008
Trypanosoma cruzi, a parasite that causes Chagas disease, is endemic in parts of Mexico, South and Central America. Transmission of T. cruzi infection by solid organ transplantation has been reported in Latin America and United States1 (Figure 1). Our laboratory began to test organ donors for anti-T. cruzi using FDA’s approved EIA on April 15, 2007
|
|
5/31/2008
There is currently a lack of predictive methods to define glucocorticoid (GC) sensitivity, which is extremely variable among individuals. In particular, identifying patients in whom steroids will have immunosuppressive and toxic activities is important in transplantation. Therefore we have sought to establish an in vitro pharmacokinetic assay to investigate leukocyte proliferation and cytokine production, with the intention of applying such a test in transplantation.
|
|
5/31/2008
Polyomavirus-associated nephropathy often precedes renal allograft dysfunction in adult renal transplant recipients. The Organ Procurement and Transplant Network/ the United Network for Organ Sharing (OPTN/UNOS) began collecting information regarding polyomavirus test results using follow-up forms since June 30, 2004. The aim of this study was to evaluate the impact of clinical polyomavirus disease (PVD) on graft survival after pediatric kidney transplantation.
|
|
|